Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB004 Phase 1b in active ulcerative colitis
NCT03860896Phase 1Completed
- Sponsor
- Gossamer Bio
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of GB004 in ulcerative colitis (UC), sponsored by Gossamer Bio. Primary endpoint: Incidence of treatment emergent adverse events at 56 Days. Started Apr 2019; status: completed.
02
Drugs
GB004
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03860896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860896.